Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa

NCT ID: NCT04325607

Last Updated: 2023-12-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-01
• Study Completion Date: 2023-10-01

Brief Summary

The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect. The soft tissue defect will then be managed with Negative Pressure Wound Therapy (NPWT) to promote healthy granulation tissue formation for wound coverage with Split skin graft (SSG). This long interval between excision and reconstruction could result in long in-patient stay, increased risk of hospital acquired infection and reduced patients' quality of life.

The investigators wish to evaluate the use of Negative Pressure Wound Therapy with instillation (NPWTi), which has potential to allow early wound coverage with SSG, as an alternative to the current standard of care. The investigators hypothesise that NPWTi reduces bacterial load on the wound and allows early wound coverage hence improves patient satisfaction and reduces cost and length of hospital stay.

Detailed Description

HS is a recurring chronic skin disease of the hair follicle that usually presents with painful and inflamed lesions in the sweat gland-bearing areas of the body. The lesions often progress to become chronic with pus discharge and scar formation resulting in significant disability.

Current surgical management for severe HS involves surgical removal of all involved hair bearing skin resulting in large areas of soft tissue loss which requires reconstruction. The wound is reconstructed by performing skin grafting, known as SSG, whereby a healthy layer of skin is transferred to the area of tissue loss. SSG enables rapid wound healing and has low risk of recurrence of HS. Skin grafting is often done a few weeks after excision of HS (delayed setting) to ensure higher success rate due to the infected nature of HS. During the interval between surgical removal of areas with HS and skin grafting, the wound is managed with a suction dressing known as the Negative Pressure Wound Therapy (NPWT) to promote formation of healthy wound bed. NPWT is a form of vacuum dressing which applies continuous suction pressure on the wound to remove fluids and bacteria from the wound bed.

The NPWT is highly successful in managing such wounds, however a novel and innovative improvement to this technology with an irrigation system, the Negative Pressure Wound Therapy with instillation (NPWTi), holds promise to enhance production of healthy wound bed and further reducing bacteria and infectious materials from the wound, enabling earlier wound coverage with SSG. The NPWTi involves irrigating and soaking the wound with fluid, followed by removal of the fluid via application of suction pressure at timed, regular intervals. The goal of the instillation therapy is to enable early application of SSG as wound irrigation has long been appreciated as beneficial for cleaning contaminated wounds.

The investigators wish to evaluate the NPWTi as an alternative to NPWT for current surgical management strategy of severe HS. The investigators wish to determine if NPWTi allows early wound coverage with SSG which improves patient satisfaction and reduces length of hospital stay. This research will further our knowledge about the human wound healing process and it may help improve treatment for future patients. The investigators plan to study up to 44 patients in total.

Conditions

Hidradenitis Suppurativa

Keywords

Hidradenitis Suppurativa; Negative pressure wound therapy with instillation; Negative pressure wound therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Negative Pressure Wound Therapy with instillation

Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS

Group Type: EXPERIMENTAL

Excision of HS followed by NPWTi

Intervention Type: PROCEDURE

The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)

Negative Pressure Wound Therapy

Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS

Group Type: ACTIVE_COMPARATOR

Excision of HS followed by NPWT

Intervention Type: PROCEDURE

The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)

Interventions

Excision of HS followed by NPWTi

The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)

Intervention Type: PROCEDURE

Excision of HS followed by NPWT

The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)

Intervention Type: PROCEDURE

Other Intervention Names

VAC VERAFLO™ Therapy; VAC Therapy

Eligibility Criteria

Inclusion Criteria

1. Male and female

2. Age 18-90 at the time of consent

3. Clinical diagnosis of axillary hidradenitis suppurativa

4. Unilateral axillary hidradenitis suppurativa (if bilateral disease, only one side will be included into study).

5. Hidradenitis suppurativa with multiple sinuses which are not able to close directly

6. Not on antibiotics for 6 weeks

7. Patient understands and is willing to participate

Exclusion Criteria

1. Hidradenitis suppurativa with isolated sinus for direct closure

2. Patient with ongoing chemotherapy or radiotherapy

3. Patient with active cancer

4. Uncontrolled Diabetes Mellitus, as measured by an HbA1c > 10%.

5. BMI over 35

6. Active smoker

7. Presence of one or more medical conditions, including renal, hepatic, hematologic, active auto-immune or immune diseases that, would make the subject an inappropriate candidate for this wound healing study

8. Patient not fit for surgery (ASA classification > 4)

9. Patients not able to consent for procedure in English

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

KCI Europe Holding B.V.

INDUSTRY

Sponsor Role: collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ash Mosahebi

Role: STUDY_DIRECTOR

Royal Free NHS Foundation Trust London

Locations

Royal Free NHS Foundation Trust Hospital London

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

247179

Identifier Type: -

Identifier Source: org_study_id